Bank of America downgrades Moderna rating due to valuation concerns – MarketWatch
Bank of America downgrades Moderna rating due to valuation concerns – MarketWatch
Shares of Moderna Inc. MRNA, -9.06% fell 8.2% on Monday after analysts at Bank of America downgraded the company’s stock rating to underperform neutral, citing valuation concerns. Until December, Moderna was a clinical-stage company that had yet to market a single treatment, but it now has one of two COVID-19 vaccines licensed in the United […]
The post Bank of America downgrades Moderna rating…
Discover more from USNewsRank
Subscribe to get the latest posts sent to your email.